Energy metabolism: Tissue determinants and cellular corollaries. Edited by J.M. Kinney and H.N. Tucker. 562 pp. New York: Raven Press, 1992. $56
Raymond S. Koff, Elihu M. Schimmel – 1 February 1993
Notices
1 February 1993
Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy
Julián Panés, Josep M. Bordas, Josep M. Piqué, Juan C. García‐pagán, Faust Feu, Josep Terés, Jaime Bosch, Joan Rodés – 1 February 1993 – This study investigated the effects of the short‐term administration of propranolol on gastric blood perfusion in cirrhotic patients with portal hypertensive gastropathy. Portal hypertensive gastropathy is a common cause of nonvariceal bleeding in cirrhosis, which is associated with increased gastric mucosal perfusion and is favorably influenced by propranolol therapy.
Atlas of Liver Pathology. G.C. Kanel and J. Korula, 285 pp. Philadelphia: W.B. Saunders Co., 1992. $140
Bruce R. Davidson – 1 February 1993
Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime
Claudio Toledo, Joan‐Manuel Salmerón, Antoni Rimola, Miquel Navasa, Vicente Arroyo, Josep Llach, Angels Ginés, Pere Ginès, Joan Rodés – 1 February 1993 – Cefotaxime is the most commonly used antibiotic for initial therapy of spontaneous bacterial peritonitis in cirrhosis. However, since the introduction of cefotaxime no study has been performed to investigate factors influencing prognosis in cirrhotic patients with this type of infection.
Stimulation of the collagen α1(I) endogenous gene and transgene in carbon tetrachloride–induced hepatic fibrosis
David A. Brenner, Linda Veloz, Rudolf Jaenisch, Joseph M. Alcorn – 1 February 1993 – Cirrhosis is characterized by a marked increase in the deposition of type I collagen and in the expression of the type I collagen genes α1(I) and α2(I). Although α1(I) gene regulation has been extensively studied in cultured cells, these results may not be applicable to hepatic fibrogenesis in vivo.
Masthead
1 February 1993
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA‐positive blood donors according to RIBA‐2 status: A case‐control survey
Lawrence Serfaty, Philippe Giral, Marie Hélène Elghouzzi, Anne Marie Jullien, Raoul Poupon – 1 February 1993 – Studies of blood donors positive for antibody to hepatitis C virus on enzyme‐linked immunosorbent assay are probably biased by the large number of false‐positive results.
Development of a bioartificial liver: Properties and function of a hollow‐fiber module inoculated with liver cells
Jacek Rozga, Frederick Williams, Man‐Soo Ro, Daniel F. Neuzil, Todd D. Giorgio, Gisela Backfisch, Albert D. Moscioni, Raymond Hakim, Achilles A. Demetriou – 1 February 1993 – We have developed a bioartificial liver support system utilizing hollow‐fiber bioreactor, plasmapheresis and microcarrier cell culture technologies. Liver cells were obtained through portal vein perfusion with ethylenediaminetetraacetate or ethylenediaminetetraacetate/collagenase.
Interferon suppresses erythromycin metabolism in rats and human subjects
Philip I. Craig, Michael Tapner, Geoffrey C. Farrell – 1 February 1993 – Interferon down‐regulates expression of cytochrome P‐450 3A in male rats. This study explored the hypothesis that interferon therefore decreases the metabolism of drugs catalyzed by cytochrome P‐450 3A. Initial experiments in male rats used microsomal erythromycin N‐demethylase activity as a probe for cytochrome P‐450 3A catalytic activity. After administration of rat interferon‐γ, erythromycin metabolism was impaired (53% of control; p < 0.01).